Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

93.61USD
17 Nov 2017
Change (% chg)

$-0.86 (-0.91%)
Prev Close
$94.47
Open
$93.80
Day's High
$94.49
Day's Low
$93.57
Volume
3,386,427
Avg. Vol
6,276,302
52-wk High
$98.26
52-wk Low
$58.60

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $149,223.20
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.71
Yield (%): 3.03

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

UPDATE 1-Novartis pitches new Cosentyx data as immunology crowd grows

* Cosentyx is now Novartis's No. 3 drug (Adds details about Cosentyx competition, comment from Novartis)

Nov 06 2017

AbbVie continues to push for reversal of latest AndroGel verdict

AbbVie Inc on Thursday renewed a motion asking a federal judge to throw out a $140 million jury verdict in a lawsuit alleging the company misrepresented the risk of its testosterone drug AndroGel.

Nov 03 2017

BRIEF-AbbVie, on conf call, says we need to see HCV market sort itself out

* AbbVie CEO, on conf call, says we need to see HCV market sort itself out

Oct 27 2017

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise

AbbVie Inc forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago, driving the U.S. drugmaker's shares up 4 percent on Friday.

Oct 27 2017

UPDATE 2-AbbVie says Humira sales will balloon to $21 bln in 2020, shares rise

* Shares up 4 percent (Adds analyst comment, updates share price)

Oct 27 2017

BRIEF-Abbvie increases quarterly dividend by 11 percent

* Sets quarterly cash dividend of $0.71 per share Source text for Eikon: Further company coverage:

Oct 27 2017

AbbVie says Humira sales will balloon to $21 bln in 2020

Oct 27 AbbVie Inc on Friday forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.

Oct 27 2017

BRIEF-Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix

* Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain

Oct 27 2017

BRIEF-AbbVie says ‍Health Canada approved inclusion of nail Psoriasis data in humira product monograph​

* AbbVie Inc says ‍Health Canada has approved inclusion of Nail Psoriasis data in Humira product monograph​ Source text for Eikon: Further company coverage:

Oct 25 2017

AbbVie bets on Alzheimer's immunotherapy with big biotech deal

U.S. drugmaker AbbVie is betting on the potential of the body's immune system to fight Alzheimer's by signing a drug development deal worth more than $200 million with unlisted biotech company Alector.

Oct 24 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Pfizer Inc. (PFE.N) $35.37 -0.19
Novartis AG (NOVN.S) CHF83.30 +0.90
Merck & Co., Inc. (MRK.N) $55.20 +0.03
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Abbott Laboratories (ABT.N) $55.56 +0.02
Eli Lilly and Co (LLY.N) $82.89 -0.55
Sanofi SA (SASY.PA) €75.43 -0.54

Earnings vs. Estimates